Positive FindingsWilding et al. 2021, NEJM (STEP 1) — a 68-week trial in 1,961 adults found 2.4mg semaglutide produced 14.9% mean weight loss vs. 2.4% on placebo. Ryan et al. 2024, Nature Medicine (SELECT) followed a larger group to 208 weeks: ~10.2% sustained weight loss, plus fewer major cardiovascular events than placebo.

Negative Findings / LimitationsBoth trials reported gastrointestinal side effects (nausea, vomiting, diarrhea) as the most common reason people stopped taking it. Separate follow-up research has found that most of the lost weight tends to return within a year of stopping the drug.

Cancer Risk — What's Actually KnownSemaglutide carries an FDA boxed warning for thyroid C-cell tumors, based on rodent studies where this drug class caused thyroid tumors, including medullary thyroid carcinoma. It's contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Whether this rodent finding translates to humans is genuinely unresolved — no confirmed causal link has shown up in human trials or surveillance so far, but long-term monitoring is ongoing and this isn't purely theoretical the way it is for most peptides on this page — it's a real, disclosed regulatory warning specific to this drug class.

Positive FindingsJastreboff et al. 2022, NEJM (SURMOUNT-1) — 72-week trial, 2,539 adults: the 15mg dose produced 20.9% mean weight loss vs. 3.1% on placebo, with a clear dose-response across the 5/10/15mg arms.

Negative Findings / LimitationsGastrointestinal side effects were the most common adverse events reported, and the trial was conducted in a supervised setting with dose escalation and lifestyle counseling, which may not reflect unsupervised use.

Cancer Risk — What's Actually KnownLike semaglutide, tirzepatide carries the same FDA boxed warning for thyroid C-cell tumors based on rodent data, and the same contraindication for anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Human relevance remains unconfirmed either way — this is a real regulatory warning for the drug class, not a theoretical mechanism concern.

Positive FindingsJastreboff et al. 2023, NEJM (Phase 2) — 48-week trial, 338 adults: the 12mg dose produced 24.2% mean weight loss vs. 2.1% on placebo. That result has since been followed up: Eli Lilly's Phase 3 TRIUMPH-1 trial (2,339 adults, 80 weeks, topline results announced May 2026) reported the 12mg dose averaged 28.3% weight loss (70.3 lbs) vs. 2.2% on placebo, with the 104-week extension in higher-BMI participants reaching up to 30.3%.

Negative Findings / LimitationsThe TRIUMPH-1 numbers above are from a company press release (topline results), not yet a peer-reviewed published paper — the only PubMed entry so far for TRIUMPH (PMID 41090431) is the trial's design/rationale paper, not its results. Retatrutide remains investigational; Lilly has stated it plans to submit for FDA approval in Q1 2027.

Cancer Risk — What's Actually KnownAs a GLP-1-class drug, retatrutide is expected to carry the same rodent-based thyroid C-cell tumor warning and contraindication (personal/family history of medullary thyroid carcinoma or MEN2 syndrome) that semaglutide and tirzepatide already carry, once it's approved. This is a documented rodent finding, not a confirmed human one, and remains unresolved either way.

Positive FindingsLau et al. 2021, The Lancet — 26-week trial: cagrilintide alone produced 6–10.8% weight loss vs. 9.0% for liraglutide and 3.0% for placebo. Frias et al. 2023, The Lancet found the CagriSema combination outperformed either drug alone in people with type 2 diabetes.

Negative Findings / LimitationsCagrilintide's effect as a standalone drug is more modest than semaglutide or tirzepatide alone; most of its documented advantage comes from being combined with another drug rather than used by itself.

Cancer Risk — What's Actually KnownCagrilintide works on amylin receptors, a different mechanism than the GLP-1 receptor pathway carrying the thyroid tumor warning — so the specific rodent thyroid C-cell signal tied to semaglutide/tirzepatide/retatrutide doesn't automatically apply to cagrilintide itself. When it's combined with semaglutide (as CagriSema), semaglutide's own boxed warning still applies to that half of the combination. No dedicated cancer signal has been reported for cagrilintide alone in its trials so far.

Positive Findingsle Roux et al. 2024, Lancet Diabetes & Endocrinology — 46-week obesity trial: dose-dependent weight loss up to 12% vs. placebo. Sanyal et al. 2024, NEJM — Phase 2 liver-disease (MASH) trial: histologic liver improvement in 47–62% of treated patients vs. 14% on placebo, with fibrosis improvement in about a third of patients.

Negative Findings / LimitationsStill an investigational drug with no FDA approval; gastrointestinal side effects were common in both trials, consistent with this drug class.

Cancer Risk — What's Actually KnownAs a GLP-1-class drug, survodutide carries the same rodent-based thyroid C-cell tumor signal as semaglutide and tirzepatide, and is expected to carry the same contraindication for anyone with a personal/family history of medullary thyroid carcinoma or MEN2 syndrome. Not confirmed in humans, and not resolved either way.

Positive FindingsJi et al. 2025, NEJM (GLORY-1) — ~14.3% mean weight loss at 48 weeks in Chinese adults with obesity. Gao et al. 2026, JAMA (GLORY-2) — 16.65% mean weight loss at 60 weeks, with improved lipids and blood pressure.

Negative Findings / LimitationsOver half of participants experienced nausea or vomiting during dose escalation. Nearly all trial data comes from Chinese populations, and it is not FDA-approved or tested in Western populations.

Cancer Risk — What's Actually KnownAs a GLP-1-class drug, mazdutide carries the same rodent-based thyroid C-cell tumor signal as semaglutide and tirzepatide. Not confirmed in humans, and not resolved either way — treat it as an open, class-wide question rather than something specific to mazdutide.

Positive FindingsHeffernan et al. 2001, Endocrinology — in obese mice, AOD9604 reduced body weight and increased fat breakdown without the blood-sugar effects of full growth hormone.

Negative Findings / LimitationsThe mouse effect disappeared in animals bred without the relevant fat-cell receptor, suggesting the mechanism is receptor-dependent. A ~300-person human trial was conducted but was only ever presented as a conference abstract — it was never published in a peer-reviewed journal, and reportedly did not separate from placebo on its main goal.

Cancer Risk — What's Actually KnownAOD-9604 was specifically engineered to keep the fat-metabolism piece of the growth hormone molecule while cutting out the piece that drives IGF-1 and broader cell growth — that IGF-1-driving piece is where the cancer-mechanism question below (see HGH) actually comes from. No cancer signal has been reported in AOD-9604's own studies, and by design it's meant to sidestep that specific concern, though this hasn't been studied at the scale needed to confirm that holds up long-term in humans.

Positive FindingsBarnhart et al. 2011, Science Translational Medicine — obese monkeys lost roughly 11% mean body weight over 28 days, with reduced waist circumference and improved insulin sensitivity confirmed by imaging.

Negative Findings / LimitationsA human Phase I trial was reportedly halted due to kidney toxicity; no peer-reviewed human safety or efficacy paper has been published.

Positive FindingsNeelakantan et al. 2018, Biochemical Pharmacology — in obese mice, 11 days of dosing reduced body weight and fat mass without changing how much they ate, alongside reduced cholesterol.

Negative Findings / LimitationsA targeted search finds zero published human trials of any kind — all available evidence is short-term rodent and cell-culture data.

YouTube VideosNo dedicated video coverage found in this library yet.

Positive FindingsVuksic et al. 2007, Surgery Today — in a rat bowel-surgery model, BPC-157 improved wound healing, with less swelling and more collagen formation than untreated controls. A 2025 human safety pilot found no adverse changes in heart, liver, kidney, thyroid, or blood sugar markers — genuine safety reassurance as far as it goes.

Negative Findings / LimitationsTwo gaps worth separating: first, that human safety study used IV infusion, not the subcutaneous injection most people actually use — so even the safety data doesn't directly cover the route it's typically taken by. Second, it was a 2-person safety check only, measuring whether the compound was safe, not whether it heals anything — the actual healing evidence is still rat-only.

Cancer Risk — What's Actually KnownThere is no known or studied cancer risk from BPC-157 in humans — no trial has looked for one, and none has reported one. The theoretical reasoning people raise is that BPC-157 promotes new blood vessel growth (angiogenesis) as part of how it helps tissue heal, and angiogenesis is also a step that established tumors need to keep growing. That's not a finding that BPC-157 causes or feeds cancer — it's just how a healing/blood-vessel-growth signal works by design: it doesn't have a way to check whether the tissue it's acting on is healthy or already cancerous. This is a mechanistic consideration, not a documented outcome.

Positive FindingsWang et al. 2021, Journal of Cellular and Molecular Medicine — first-in-human Phase I, 84 healthy volunteers, ascending doses of recombinant thymosin beta-4: no dose-limiting toxicities or serious adverse events, with predictable, dose-proportional blood levels — real, if narrow, human safety data.

Negative Findings / LimitationsTwo things that data doesn't cover: it was given by IV, not the subcutaneous injection most people actually use, so it doesn't directly speak to that route. And it measured safety and how the body processes the compound only — it did not test whether TB-500 actually speeds healing or improves recovery in injured people; that evidence still doesn't exist in humans.

Cancer Risk — What's Actually KnownNo human trial has found that TB-500/thymosin beta-4 causes cancer, and the Phase I safety trial above found no such signal. This one is worth being a bit more precise on than most, though: separate cancer-biology research (not trials of the peptide as a therapy) has found that thymosin beta-4 is elevated in several tumor types and has been linked to increased cell migration and invasiveness in lab studies of cancer cells — the same actin-regulating, cell-movement mechanism that makes it useful for wound healing is mechanistically the same one implicated in how cancer cells spread. That's an observed association in cancer-biology research, not evidence that taking TB-500 causes cancer, and no study has tested that direct question in people using it as a supplement or peptide therapy.

Positive FindingsGHK-Cu naturally declines with age, and lab/animal research has genuinely linked it to increased collagen signaling, faster wound closure, and antioxidant activity — this is real, published mechanism research, and it's the basis for GHK-Cu's reputation as a skin-repair peptide.

Negative Findings / LimitationsThe catch is route: Miller et al. 2006, Archives of Facial Plastic Surgery — the one controlled human trial — applied GHK-Cu topically as a post-laser skincare product, not by injection, and even there found no significant objective improvement in redness or wrinkles versus standard care (only higher patient-reported satisfaction). Most vendors sell GHK-Cu for subcutaneous injection, and that specific route has no human trial behind it at all — the topical evidence doesn't automatically transfer to it. A widely repeated online claim of a "28% collagen increase" study also doesn't correspond to any real, matching PubMed record when checked directly.

Cancer Risk — What's Actually KnownThere is no known or studied cancer risk from GHK-Cu in humans. GHK-Cu is also a somewhat different case than a pure growth signal — separate gene-expression research on it has actually found it shifts a broad set of genes toward tissue-repair and anti-inflammatory patterns, with some of that research specifically looking at (and not finding) cancer-promoting gene activity. That's reassuring as far as it goes, but it comes from gene-expression lab studies, not a human cancer-outcomes trial — nobody has actually tracked cancer rates in long-term GHK-Cu users, so "no known risk" reflects an absence of that kind of study as much as it reflects clean data.

Positive FindingsPyo et al. 2007, Archives of Pharmacal Research — human scalp hair follicles and dermal papilla cells: AHK-Cu stimulated follicle elongation and cell growth, and increased the ratio of cell-survival to cell-death signaling proteins.

Negative Findings / LimitationsThis is an ex vivo/in vitro study only — isolated follicles and cells outside the body, not a trial measuring hair regrowth on an actual person's scalp.

Cancer Risk — What's Actually KnownThere is no known or studied cancer risk from AHK-Cu — no study has looked for one either way, since research on it is limited to isolated cells in a dish. The same reasoning that applies to GHK-Cu (it's a growth/cell-survival signal that doesn't distinguish tissue type) would theoretically apply here too, but this hasn't been studied enough to say more than that.

YouTube VideosNo dedicated video coverage found in this library yet.

Positive FindingsDalmasso et al. 2008, Gastroenterology — in human intestinal cell lines and two mouse colitis models, KPV reduced inflammatory signaling and cytokine levels, and oral KPV reduced colitis severity in the mice. Kannengiesser et al. 2008, Inflammatory Bowel Diseases — separate mouse IBD models: faster weight recovery and less tissue damage with KPV treatment.

Negative Findings / LimitationsBoth studies are mouse models and human cell cultures — no published human clinical trial of KPV for gut health exists.

Positive FindingsDjillani et al. 2017, Frontiers in Pharmacology — mouse depression-behavior models: reduced despair-like and anxiety-like behavior, increased hippocampal cell growth within 4 days, and lasted longer in the body than its parent compound, spadin.

Negative Findings / LimitationsAll available evidence is in mice — no completed human depression or mood trial has been published.

Positive FindingsHeij et al. 2012, Molecular Medicine — placebo-controlled trial, 22 sarcoidosis patients with small-fiber neuropathy symptoms: significant improvement in nerve-pain symptom scores and quality-of-life measures, with no safety concerns over 4 weeks.

Negative Findings / LimitationsThis remains a small, 22-patient pilot study for one specific rare-disease population; it is not FDA-approved, and broader "nerve regeneration" or general anti-aging claims go beyond what this trial tested.

Cancer Risk — What's Actually KnownARA-290 was specifically engineered from erythropoietin to strip out EPO's red-blood-cell-boosting activity (which is where EPO's own documented tumor-progression concern comes from — see the EPO entry) while keeping the separate tissue-protective signal. No cancer signal has been reported in ARA-290's own trials, and by design it's meant to avoid the specific mechanism that raises the question for EPO itself — though this hasn't been studied at the scale needed to confirm that holds up long-term.

Positive FindingsMizoguchi et al. 2011, Peptides — dermorphin-derived analogs produced stronger, longer-lasting pain relief than morphine in animal pain models, with a receptor profile the authors suggest may carry less dependence risk.

Negative Findings / LimitationsRobinson et al. 2015, Journal of Veterinary Pharmacology and Therapeutics — the underlying pharmacokinetics study was done in horses, as part of doping-detection research, since dermorphin is a banned racehorse substance. No human safety or efficacy trial exists.

Positive FindingsRobinson et al. 2005, International Journal of Cosmetic Science — 12-week, placebo-controlled, split-face RCT in 93 women aged 35-55: significant improvement in wrinkles and fine lines vs. placebo, well tolerated.

Negative Findings / LimitationsThe tested concentration was low (3ppm), and the improvement, while statistically real, was modest — well short of the large percentage figures (like "68% wrinkle reduction") often quoted in marketing, which trace to manufacturer materials rather than this published trial.

Positive FindingsTwo human trials (Ann Dermatol 2024, J Cosmet Dermatol 2020) using multi-ingredient microneedle patches containing Snap-8 alongside other peptides reported measurable wrinkle improvement.

Negative Findings / LimitationsNo standalone human trial of Snap-8 by itself exists — both studies tested it only as one ingredient in a blend, and the authors credited the overall formula rather than isolating Snap-8's individual contribution.

Positive FindingsSalomon et al. 1989, NEJM — placebo-controlled trial in 24 adults with diagnosed GH deficiency: 6 months of hGH produced +5.5kg lean mass and −5.7kg fat mass, with no change in the placebo group.

Negative Findings / LimitationsThis strong result is specific to adults with a diagnosed medical deficiency; HGH used in healthy adults carries real risks including joint pain, fluid retention, and elevated blood sugar, and there is far less controlled trial evidence for anti-aging or athletic use in people with normal GH levels.

Cancer Risk — What's Actually KnownThis is one of the few entries on this page where there's real human epidemiological data, not just a theoretical mechanism: people with acromegaly (a condition causing chronically elevated GH and IGF-1 for years) show a documented increase in certain cancers, particularly colorectal, in long-term population studies. GH works largely by raising IGF-1, a growth factor that promotes cell division broadly — it doesn't have a way to distinguish a healthy cell dividing from an undetected cancer cell doing the same thing, which is the actual mechanism behind the concern. That said, this is specifically about years of chronically elevated levels (as in acromegaly), and there's no equivalent long-term outcome data for people cycling HGH at typical wellness/anti-aging doses — the acromegaly data shows the mechanism is real, not that any given dosing pattern carries the same risk.

Positive FindingsHeffernan et al. 2001, International Journal of Obesity — mouse study of the closely related fragment AOD9604: reduced weight gain and increased fat breakdown without full HGH's blood-sugar side effects.

Negative Findings / LimitationsNo study of this exact fragment in humans exists at all — the only supporting data is a mouse study of a related, but not identical, compound.

Cancer Risk — What's Actually KnownSame reasoning as AOD-9604 (the closely related fragment it's tested alongside): this piece of the GH molecule was specifically isolated because it excludes the region that drives IGF-1 and broader cell growth — the part of full HGH where the actual documented cancer-mechanism concern comes from (see the HGH entry). No cancer signal has been reported for this fragment, and by design it's meant to sidestep that specific pathway, though it hasn't been studied at the scale needed to confirm that in humans.

Positive FindingsKhorram, Laughlin & Yen 1997, JCEM — 5-month placebo-controlled trial, 19 adults aged 55-71: increased nightly GH and IGF-1, and improved skin thickness, lean body mass, and insulin sensitivity, with a larger benefit in men than women.

Negative Findings / LimitationsThis is a small (19-person), older trial; sermorelin's original branded product (Geref) was discontinued for business reasons, and modern, larger placebo-controlled trials in healthy adults are lacking.

Cancer Risk — What's Actually KnownSermorelin and the rest of this GH-secretagogue family (Tesamorelin, CJC-1295, Ipamorelin, GHRP-2, GHRP-6, Hexarelin) work by prompting your own pituitary to release GH, which then raises IGF-1 — the same growth signal discussed under HGH, where real human epidemiological data (from acromegaly patients) links years of chronically elevated GH/IGF-1 to increased colorectal cancer risk. Worth noting the mechanism is different here, though: these peptides trigger your body's own regulated, pulsatile release rather than overriding it with a constant external dose, which in theory should stay inside the body's normal negative-feedback limits better than injecting HGH directly. That's a plausible distinction, not a proven one — nobody has run the acromegaly-style long-term cancer-outcome study on secretagogue users specifically, so it remains a mechanistic consideration rather than an established finding either way.

Positive FindingsFalutz et al. 2007, NEJM — Phase 3 RCT, 412 HIV patients, 26 weeks: tesamorelin significantly reduced visceral fat and improved triglycerides vs. placebo, with good tolerability.

Negative Findings / LimitationsThe approval is specific to HIV-associated lipodystrophy; there is much less controlled trial evidence for general anti-aging, athletic, or cosmetic use outside that population, and visceral fat has been shown to return after stopping treatment.

Cancer Risk — What's Actually KnownSame GH/IGF-1 mechanism question as the rest of this family (see Sermorelin, above, for the full explanation) — tesamorelin raises your own GH and downstream IGF-1, the growth signal linked to increased cancer risk in people with chronically elevated levels for years (acromegaly). Its own approval trial didn't run long enough or wasn't designed to detect a cancer signal either way; the FDA label does note it hasn't been studied in people with a history of cancer.

Positive FindingsTeichman et al. 2006, JCEM — ascending-dose trials in healthy adults: CJC-1295 produced sustained 2-10x GH increases lasting 6+ days and raised IGF-1 for 9-11 days, with no serious adverse events over 49 days of repeat dosing.

Negative Findings / LimitationsThis trial measured blood hormone levels only — it did not measure muscle mass, strength, fat loss, or anti-aging outcomes.

Cancer Risk — What's Actually KnownSame GH/IGF-1 question as the rest of this family (see Sermorelin, above) — CJC-1295's own trial confirmed it raises IGF-1 for 9-11 days per dose, which is the growth signal the acromegaly data ties to increased cancer risk over years of chronic elevation. No cancer-outcome study exists for CJC-1295 users specifically.

Positive FindingsGobburu et al. 1999, Pharmaceutical Research — single-dose PK study in healthy men: ipamorelin reliably produced one self-limited GH pulse with dose-proportional response and a roughly 2-hour half-life.

Negative Findings / LimitationsBeck et al. 2014, International Journal of Colorectal Disease — a Phase 2 trial testing ipamorelin for post-surgery GI recovery did not significantly improve outcomes vs. placebo. No trial has tested muscle, fat-loss, or anti-aging outcomes directly.

Cancer Risk — What's Actually KnownSame GH/IGF-1 question as the rest of this family (see Sermorelin, above) — ipamorelin's whole mechanism is triggering a GH pulse, which raises IGF-1 downstream. No cancer-outcome study exists for ipamorelin users specifically, and its selectivity for the ghrelin receptor doesn't change what IGF-1 itself does once it's released.

Positive FindingsLaferrère et al. 2005, JCEM — 7 healthy men: GHRP-2 increased food intake by 35.9% and raised GH significantly versus saline.

Negative Findings / LimitationsMericq et al. 2003 — a 12-month trial in GH-deficient children found appetite increased, but the change in BMI was not statistically significant.

Cancer Risk — What's Actually KnownSame GH/IGF-1 question as the rest of this family (see Sermorelin, above) — GHRP-2 raises GH and downstream IGF-1 by design. No cancer-outcome study exists for GHRP-2 users specifically.

Positive FindingsBellone et al. 1995, European Journal of Endocrinology — 13 short-stature children: oral GHRP-6 produced a GH response statistically comparable to IV GHRH, demonstrating it works even taken by mouth.

Negative Findings / LimitationsThis trial was conducted in children with short stature, not healthy adults, tested oral dosing rather than the subcutaneous injection most people actually use, and measured a single GH-release response rather than muscle, fat, or long-term outcomes.

Cancer Risk — What's Actually KnownSame GH/IGF-1 question as the rest of this family (see Sermorelin, above) — GHRP-6 raises GH and downstream IGF-1 by design, and its hunger-boosting side effect (via the ghrelin receptor) doesn't change what IGF-1 itself does once released. No cancer-outcome study exists for GHRP-6 users specifically.

Positive FindingsImbimbo et al. 1994, European Journal of Clinical Pharmacology — 12 healthy men, single IV doses: hexarelin produced a strong, dose-dependent GH spike peaking around 30 minutes, confirming potent acute GH-releasing activity.

Negative Findings / LimitationsThis trial used a single IV dose, not the subcutaneous injection most people actually use, and there is no controlled human data on body composition, cardiac, or long-term outcomes. Animal research on GHRP-class compounds has also raised questions about tolerance (reduced response) with repeated use.

Cancer Risk — What's Actually KnownSame GH/IGF-1 question as the rest of this family (see Sermorelin, above), and hexarelin is the most potent GH-releasing compound in this group — meaning it drives the largest acute rise in the downstream IGF-1 signal the acromegaly data ties to cancer risk over years of chronic elevation. No cancer-outcome study exists for hexarelin users specifically.

Positive FindingsTomas et al. 1994, Biochemical Journal — in rats, LR3-IGF-I combined with insulin improved overall weight gain more than insulin alone.

Negative Findings / LimitationsTomas et al. 2001, Growth Hormone & IGF Research — LR3-IGF-I alone did not improve muscle protein specifically, and in adult rats it actually increased muscle protein breakdown. No human safety or efficacy data exists at all.

Cancer Risk — What's Actually KnownThis is the most direct version of the cancer-mechanism question on this whole page: IGF-1 LR3 isn't something that raises IGF-1 indirectly (like the GH secretagogues above) — it's a modified, longer-acting form of IGF-1 itself, engineered specifically to be more potent and harder for the body to clear. IGF-1 is the exact growth signal the acromegaly data (see HGH) ties to increased cancer risk with years of chronic elevation, and this version is designed to stay active in the body longer than natural IGF-1 does. There is no cancer-outcome study on IGF-1 LR3 users, and given there's no human safety data of any kind here, that gap matters more for this compound than most others on this page.

Positive FindingsKandalla et al. 2011, Mechanisms of Ageing and Development — human muscle satellite-cell cultures: MGF-E extended proliferative lifespan and improved fusion potential of these repair cells across donor age groups.

Negative Findings / LimitationsThis is a cell-culture study only — no human injection trial has tested whether MGF actually increases muscle growth in a living person.

Cancer Risk — What's Actually KnownMGF is a splice variant of IGF-1 (see IGF-1 LR3 and HGH, above, for the underlying concern) — same growth-factor family, though MGF's natural role is more localized to the muscle tissue under mechanical stress rather than circulating broadly. No cancer signal has been reported, but that's also because it's never been tested in a living person at all, let alone tracked for long-term outcomes.

Positive FindingsPlain (non-pegylated) MGF has cell-culture support, as shown in the MGF entry above — the pegylation is intended to extend that same signal's effect for longer.

Negative Findings / LimitationsNo verifiable study of the pegylated peptide itself exists. A related paper used a PEG-based delivery device for plain MGF — a different thing entirely — and a commonly cited PMID for a "PEGylated MGF" rat study was checked directly and belongs to an unrelated mosquito genetics paper.

Cancer Risk — What's Actually KnownSame underlying question as MGF and IGF-1 LR3 (an IGF-1-family growth signal) — with the added wrinkle that pegylation is specifically meant to make it last longer in the body, which would extend however long that signal is active. No study exists to say anything more specific than that.

Positive FindingsGonzalez Trotter et al. 2025, Nature Communications — Phase 1 RCT in postmenopausal women and men: antibodies blocking both GDF-8 (myostatin) and activin A increased muscle mass and reduced fat mass vs. placebo, with good tolerability.

Negative Findings / LimitationsThe clinical benefit here comes specifically from blocking myostatin, not from administering it — myostatin itself is the muscle-limiting signal, so taking the protein directly would work against muscle growth, not for it.

Cancer Risk — What's Actually KnownMyostatin is part of a different signaling family (TGF-beta) than the GH/IGF-1 growth axis discussed elsewhere on this page, and it isn't tied to the same acromegaly-style cancer data. TGF-beta family signaling does play a complex, dual role in cancer biology generally (it can suppress early tumor growth and promote later-stage tumors, depending on context), but that's a separate research question from whether blocking myostatin specifically raises cancer risk — no study has found that it does.

Positive FindingsMendell et al. 2015, Molecular Therapy — Becker muscular dystrophy patients given follistatin gene therapy: 2 of 6 showed meaningful walking-distance improvement and reduced muscle fibrosis on biopsy at one year. Mendell et al. 2017 — inclusion body myositis patients: treated group gained walking distance over a year vs. a declining comparison group.

Negative Findings / LimitationsBoth studies used gene therapy delivered directly into muscle in people with diagnosed muscle disease — not peptide injections in healthy people — and benefit was seen in only a small number of the treated patients.

Cancer Risk — What's Actually KnownSame as GDF-8/myostatin, above — follistatin works on a different pathway (TGF-beta family, not the GH/IGF-1 axis) that doesn't carry the same acromegaly-style cancer data, though the broader TGF-beta family does play a complex role in cancer biology generally. No study has found that blocking myostatin/activin with follistatin raises cancer risk.

Positive FindingsCampbell et al. 2017, Muscle & Nerve — RCT in boys with Duchenne muscular dystrophy: a trend toward preserved walking distance, plus increased lean mass and bone density vs. placebo.

Negative Findings / LimitationsThe trend in walking distance was not statistically significant, and the trial was halted early after vascular side effects (nosebleeds, small dilated blood vessels under the skin) appeared in treated participants.

Cancer Risk — What's Actually KnownSame pathway as GDF-8/myostatin and follistatin, above (TGF-beta family, not the GH/IGF-1 axis) — no cancer signal has been reported for ACE-031, though its trial was stopped early for a different safety issue (the vascular side effects noted above) before long-term questions like this could really be assessed.

Positive FindingsInsulin is a well-established, life-sustaining medication with decades of clinical use for diabetes; its muscle-building rationale is that it drives glucose and amino acids into muscle cells.

Negative Findings / LimitationsIp et al. 2012, Current Sports Medicine Reports — survey of 41 nondiabetic bodybuilding-community insulin users: 56.8% experienced hypoglycemia, including one who lost consciousness, and most obtained it without a prescription. Mistimed insulin use can cause severe, fast-onset low blood sugar, which is medically dangerous.

Cancer Risk — What's Actually KnownInsulin and IGF-1 share overlapping receptors, and at the high, non-physiological doses sometimes used for bodybuilding, insulin can cross-activate IGF-1 receptors — the same growth pathway discussed under HGH and IGF-1 LR3. Some population studies have also found associations between long-term high-dose insulin therapy and certain cancers in diabetic patients, though that research is complicated by the fact that diabetes itself is separately linked to some cancer risk. Nothing here establishes that bodybuilding-style insulin use causes cancer — but for insulin specifically, the more immediate and far better-documented danger is the hypoglycemia above, which can kill someone in a single mistimed dose long before a theoretical long-term risk would matter.

YouTube VideosNo dedicated video coverage found in this library yet.

Positive FindingsKhavinson et al. 2003, Bulletin of Experimental Biology and Medicine — human fibroblasts: activated telomerase, elongated telomeres in the dish. Khavinson et al. 2002 — a small, unblinded human trial in retinitis pigmentosa reported a "positive clinical effect" in ~90% of cases.

Negative Findings / LimitationsThe retinitis pigmentosa trial was small, unblinded, and single-institution. A 2025 review notes most older clinical data actually used a related but different compound ("Epithalamin," a pineal-extract drug), not the synthetic tetrapeptide sold today — and no large trial of the synthetic version's effect on aging or telomeres in generally healthy people has been conducted.

Cancer Risk — What's Actually KnownThis is the one entry on this page where the mechanism itself deserves extra attention, not just a passing note: Epithalon's studied effect is activating telomerase and lengthening telomeres. Reactivating telomerase is also one of the well-established "hallmarks of cancer" — it's the specific mechanism most cancer cells use to become effectively immortal and keep dividing indefinitely, which is exactly why normal cells keep telomerase switched off as they age. There is no study showing Epithalon causes cancer in humans or animals, and no trial has been designed to test for it either. But this isn't a vague "everything is theoretically risky" caveat the way it is for most entries on this page — turning telomerase back on is mechanistically the same switch that a large share of human cancers depend on, and that overlap hasn't been specifically studied for this compound.

Positive FindingsKaraa et al. 2020 — in mitochondrial myopathy patients, fatigue and quality-of-life scores improved on SS-31 vs. placebo. ReCLAIM-2, 2024 — in dry macular degeneration, SS-31 showed enhanced preservation of a key photoreceptor-loss marker (ellipsoid zone attenuation), a secondary finding strong enough that it's now the primary endpoint for the compound's Phase 3 eye-disease program. TAZPOWER open-label extension, 2024 — in Barth syndrome patients followed for up to 168 weeks without a placebo group, median knee extension strength improved by 63 newtons and functional walking distance increased. That open-label result, not the earlier placebo-controlled phase, is what supported the FDA's September 2025 accelerated approval — making SS-31/elamipretide the first mitochondria-targeted drug the FDA has ever approved, under the brand name Forzinity.

Negative Findings / LimitationsEvery rigorous placebo-controlled trial of SS-31 has missed its primary endpoint, including the three studies cited above in their controlled phases. Beyond those, a Phase 3 trial in 218 people with primary mitochondrial myopathy (MMPOWER-3) showed no overall improvement in walk distance or fatigue vs. placebo at the standard 40mg/day dose; a trial during acute heart attacks (EMBRACE-STEMI) found no reduction in heart muscle damage; and a heart-failure trial (PROGRESS-HF) showed only a modest, statistically uncertain effect on heart chamber size with no biomarker improvement. The FDA's approval is an "accelerated approval," granted on a single open-label, no-placebo result in 12 rare-disease patients, and is conditional on a confirmatory trial — it can be withdrawn if that trial fails to confirm a real-world benefit.

Cancer Risk — What's Actually KnownThere is no known or documented cancer risk associated with SS-31 in any human trial to date, including a Phase 3 study with over 200 participants. That said, its core mechanism is anti-apoptotic — it works partly by blocking the mitochondrial permeability transition pore, one of the switches that tells a damaged cell to self-destruct. That switch doesn't distinguish between a healthy cell you want protected and a damaged or abnormally dividing cell your body may be trying to eliminate through that exact same pathway — by design, SS-31 has no way to tell those cells apart. This is a theoretical, mechanism-based consideration rather than an observed signal: none of its trials, including the largest ones, have flagged any increase in cancer rates, but none were designed or run long enough to specifically detect a slow-developing cancer risk either.

Positive FindingsD'Souza et al. 2020, Aging — in healthy men, skeletal-muscle MOTS-c expression was higher in older and middle-aged men and correlated with a favorable muscle-fiber composition. Hyatt 2022 — in mice, a single injected dose improved untrained running duration by 12% and distance by 15%.

Negative Findings / LimitationsThe human data is observational (natural levels only, not testing the injected peptide), and a 2026 human exercise study could not confirm that skeletal muscle actually releases MOTS-c into the bloodstream during exercise, which the injectable-peptide theory depends on. (A new Phase 2a human trial, NCT07505745, is registered but has no published results yet.)

Positive FindingsRichie et al. 2015 — 54 healthy adults, 6 months: 1,000mg/day oral glutathione raised body GSH stores 30-35% and more than doubled natural killer cell activity vs. placebo. Kalamkar et al. 2022 — 250 elderly type 2 diabetics: glutathione supplementation improved HbA1c (blood sugar control) and reduced oxidative DNA damage.

Negative Findings / LimitationsAllen & Bradley 2011 — in healthy adults specifically, oral glutathione supplementation produced no significant change in oxidative stress biomarkers, suggesting the clearest measured benefit so far is in people with existing metabolic issues, not in already-healthy people.

Cancer Risk — What's Actually KnownThere's no evidence glutathione supplementation causes cancer. The relevant nuance runs the other way: separate cancer-biology research has found that some tumors actually raise their own internal glutathione levels as a way to resist chemotherapy's oxidative damage — meaning glutathione's protective, antioxidant role for healthy cells could theoretically extend the same protection to cancer cells already present, including possibly blunting chemo effectiveness in someone undergoing cancer treatment. That's a mechanistic consideration from cancer biology, not a finding that supplementing glutathione causes or worsens cancer in a healthy person.

Positive FindingsBaar et al. 2017, Cell — in naturally aged and chemotherapy-damaged mice, FOXO4-DRI restored running endurance, fur density, and kidney function, selectively triggering death in senescent cells without harming healthy ones. Huang et al. 2021 — in a dish, it selectively cleared senescent human cartilage cells (chondrocytes) while sparing healthy proliferating cells.

Negative Findings / LimitationsNo human clinical trial of any kind has been conducted — all evidence is limited to mice and one isolated human cell-culture experiment.

Cancer Risk — What's Actually KnownThis one is actually a bit different from most growth/repair peptides on this page: FOXO4-DRI works by freeing up p53 (a major tumor-suppressor gene) specifically inside senescent cells, triggering those damaged cells to self-destruct — by design, that's closer to a targeted "clean-up" mechanism than a generalized growth signal that doesn't discriminate. Some cancer researchers even think clearing senescent cells could be protective, since senescent cells can release factors that help nearby tumors grow. That said, p53 is about as high-stakes a pathway as exists in cancer biology, and no human study has looked at what happens when this specific mechanism interacts with cells that already have abnormal p53 (which includes early cancer cells) — so "actually reassuring by design" and "genuinely untested in a person" are both true at once here.

Positive FindingsKaru et al. 2015 — in cardiac surgery patients, a brief period of high-oxygen ventilation raised expression of the body's own humanin genes in heart tissue, suggesting a stress-protective role.

Negative Findings / LimitationsVoigt & Jelinek 2016 — this and other human data are purely observational (measuring natural humanin levels, which were lower in patients with impaired fasting glucose) — no trial has tested injecting synthetic humanin into people.

Cancer Risk — What's Actually KnownThere's no known or studied cancer risk from humanin in humans — nobody has looked, since it's never been tested as an injectable therapy in people. The mechanistic reasoning worth knowing: humanin works by protecting cells from apoptosis (programmed cell death) under stress. Evading apoptosis is one of the defining traits cancer cells need to survive and keep dividing, so a signal that broadly protects cells from dying doesn't have a built-in way to exclude an already-abnormal cell from that same protection. That's how the mechanism works by design, not evidence that humanin causes or promotes cancer — it just hasn't been ruled out either, because it hasn't been studied in people at all.

Positive FindingsMuresanu et al. 2016 (CARS trial) — in acute ischemic stroke patients, daily Cerebrolysin plus standard rehab produced significantly better motor-function recovery at day 90 than placebo. Panisset et al. 2002 — in Alzheimer's patients, it showed a modest benefit on one global-function scale.

Negative Findings / LimitationsA 2020 Cochrane systematic review of stroke trials found no clear overall benefit, and moderate-quality evidence of more non-fatal serious adverse events in the Cerebrolysin group than placebo.

Positive FindingsZozulia et al. 2008 — in 62 patients with generalized anxiety and neurasthenia, Selank's anxiolytic effect was comparable to the benzodiazepine medazepam, with added antiasthenic (anti-fatigue) effects.

Negative Findings / LimitationsThis is a single, decades-old Russian trial that does not appear to have been independently replicated in a placebo-controlled Western study, and it compared Selank to an older sedative rather than to a placebo.

Positive FindingsGusev et al. 1997 and 2018 — in ischemic stroke patients, intranasal Semax as add-on therapy improved motor/functional recovery and raised plasma BDNF (a protein linked to neuron growth). Ivanikov et al. 2002 — in peptic ulcer patients, adding Semax to standard medication produced 89.5% healing vs. 30.8% in controls.

Negative Findings / LimitationsAll human trials are in Russian stroke-rehabilitation and ulcer patients — none test cognitive enhancement in healthy people, which is how it's most commonly marketed in the West, and none have been independently replicated outside Russia.

Positive FindingsSchneider-Helmert & Schoenenberger 1981 and a related 1981 crossover trial — in healthy volunteers and chronic insomniacs given a single dose, DSIP increased total sleep time and reduced nighttime awakenings.

Negative Findings / LimitationsIn the population it's actually marketed to, results are weaker: Monti et al. 1987 found the sleep improvement in chronic insomniacs "of little clinical significance," and Bes et al. 1992 found the effect weak and possibly confounded by a change in the placebo group. No large modern trial exists.

Positive FindingsKhavinson et al. 2011 — in rat brain cells exposed to oxidative stress, Pinealon reduced free-radical damage and cell death in a dose-dependent way. A 2015 human trial giving Pinealon together with Vesugen to 32 elderly patients reported improved anabolic/CNS-activity markers.

Negative Findings / LimitationsThe cell-based evidence is in rats, not people. The one human trial tested Pinealon only in combination with Vesugen, in a tiny, unblinded cohort — Pinealon showed a smaller effect than its partner, and has never been tested alone in humans.

Positive FindingsKhavinson, Lin'kova & Umnov 2021 — in Alzheimer's-disease lab models, the KED peptide (Vesugen) restored synaptic plasticity and regulated genes tied to neurogenesis and apoptosis. The same 2015 human trial covered under Pinealon found Vesugen showed the more visible of the two peptides' effects on cognitive/CNS markers in elderly patients.

Negative Findings / LimitationsVesugen has never been tested alone in a human trial — only combined with Pinealon in one small, unblinded study — and no dedicated human trial exists for its specific vascular/cardiovascular claims.

Positive FindingsAn older 1985 trial in 42 post-radiotherapy lung-cancer patients found Tα1 normalized T-cell function versus no improvement on placebo, correlating with better relapse-free survival in a nonbulky-tumor subgroup.

Negative Findings / LimitationsThe largest and most recent trial — Wu et al. 2025, BMJ (TESTS trial), 1,106 sepsis patients — found no mortality benefit at all (23.4% vs. 24.1%, not statistically significant). Broad "immune supercharger" framing outpaces what a modern, large, well-controlled trial has actually shown.

Positive FindingsKhavinson et al. 2020 — in human hematopoietic stem cell samples, thymalin shifted marker expression toward T-cell maturation. Govorin & Stupina 1990 — adding thymalin to standard medication in treatment-resistant schizophrenia patients with immune abnormalities was linked to reported symptom improvement.

Negative Findings / LimitationsBoth studies are small, older, and Russian-only; neither is a large, modern, placebo-controlled trial of the kind that would validate anti-aging or general immune-support claims.

Positive FindingsGrönberg et al. 2014, Wound Repair and Regeneration — in a first-in-human placebo-controlled trial, 34 patients with chronic venous leg ulcers treated with topical LL-37 showed significantly higher healing rates, with lower doses (0.5 and 1.6 mg/mL) outperforming a higher dose and no safety concerns.

Negative Findings / LimitationsThis trial tested only topical use for one specific type of chronic wound — it says nothing about systemic immune support, gut health, or anti-aging, which is how LL-37 is often marketed more broadly.

Cancer Risk — What's Actually KnownNo trial of LL-37 as a therapy has found it causes cancer. Separate cancer-biology research on this molecule (not trials of it as a treatment) has found a genuinely mixed picture: LL-37 has been associated with promoting growth and spread in some cancers (like ovarian and breast, in lab studies) while appearing to suppress others — it doesn't have one consistent direction the way a simple "growth signal" story would suggest. That mixed research exists at the level of tumor biology, not as evidence that using topical LL-37 for wound healing causes cancer.

Positive FindingsSarafraz-Yazdi et al. 2010, PNAS — in cultured human cancer cell lines (breast, pancreatic, melanoma), PNC-27 selectively destroyed cells carrying a specific marker (membrane-bound HDM-2) while sparing normal, untransformed cells.

Negative Findings / LimitationsThis is entirely preclinical, in vitro and ex vivo evidence — no human clinical trial of any kind has been conducted.

Positive FindingsChervyakova, Linkova & Chalisova 2014 — in laboratory aging spleen tissue, Crystagen activated B-cells (a type of immune cell).

Negative Findings / LimitationsThe same study found it did not enhance overall tissue cell renewal, and this remains a single narrow tissue-level lab study — no human clinical trials of any kind exist.

YouTube VideosNo dedicated video coverage found in this library for this specific compound.

Positive FindingsKingsberg et al. 2019, Obstetrics & Gynecology (RECONNECT trials) — two Phase 3 trials, 1,267 premenopausal women with diagnosed hypoactive sexual desire disorder: significant increase in sexual desire and reduced related distress vs. placebo. This formed the basis of FDA approval.

Negative Findings / LimitationsNausea, flushing, and headache were common (≥10% of users) in the approval trials, and the approved use is specific to premenopausal women with a diagnosed condition — off-label use in men has not been tested in the same way.

Cancer Risk — What's Actually KnownPT-141 mainly acts on melanocortin receptors in the brain (MC4R) rather than the skin-pigment receptor (MC1R) that Melanotan I/II primarily target — so the melanoma case reports described under those two entries are much less relevant here specifically. Its FDA approval trials didn't flag a cancer signal, though they also weren't designed or long enough to detect one either way.

Positive FindingsUgwu et al. 1997, Biopharmaceutics & Drug Disposition — a small pharmacokinetic study found subcutaneous dosing was fully absorbed, and produced visible tanning that lasted about 3 weeks after the last dose, with minimal short-term side effects (mild GI upset, flushing).

Negative Findings / LimitationsThis study involved only 3 people and measured short-term tanning and drug absorption — it does not establish long-term safety.

Cancer Risk — What's Actually KnownThis is a case where there's real, if limited, human evidence worth naming directly, mostly from Melanotan II (below) rather than Melanotan I specifically: published dermatology case reports exist of new or changing moles, including at least one melanoma, appearing after use of unregulated Melanotan products. Melanotan I is more selective for the pigmentation receptor than Melanotan II and has fewer such reports tied to it specifically, but the underlying mechanistic concern is the same for both — triggering melanocytes (the pigment-producing cells that melanoma arises from) to grow and produce more pigment is, by definition, stimulating the exact cell type that becomes cancerous in melanoma. This is not proof Melanotan I causes melanoma, but it's a documented, published concern, not a purely theoretical one, and anyone using it should have any new or changing moles checked by a dermatologist.

Positive FindingsDorr et al. 1996 — a 3-person pilot found spontaneous erections and visible tanning after just 5 low doses. Wessells et al. 1998 — in a placebo-controlled crossover trial, 8 of 10 men with erectile dysfunction had clinically measurable erections on Melanotan II vs. placebo.

Negative Findings / LimitationsBoth trials were small and short-term, with nausea and flushing common at higher doses — neither evaluated the long-term safety of the unregulated product sold today.

Cancer Risk — What's Actually KnownThis is the entry where that concern is most directly documented: published dermatology case reports describe new or changing moles (including at least one report of melanoma) in people using unregulated Melanotan II. Melanotan II activates melanocytes broadly (it's less selective than Melanotan I), which is exactly the mechanism — triggering melanocyte growth and pigment production — that's implicated in how melanoma develops. This isn't proof that Melanotan II causes melanoma, and no controlled trial has directly tested cancer incidence, but it's a real, published clinical concern rather than a purely mechanistic "in theory" one — anyone using it should get any new or changing moles checked by a dermatologist.

Positive FindingsYamasue et al. 2020, Molecular Psychiatry — in 106 adults with autism spectrum disorder, intranasal oxytocin reduced repetitive behaviors and increased social gaze fixation vs. placebo over 6 weeks.

Negative Findings / LimitationsThe same trial found no significant difference between oxytocin and placebo on the primary, core social-reciprocity measure — the main thing the study was designed to test.

Positive FindingsGeorge et al. 2011, JCEM — in healthy men, IV kisspeptin-10 produced a rapid, dose-dependent rise in LH, and prolonged infusion increased LH pulse frequency and testosterone.

Negative Findings / LimitationsJayasena et al. 2011 — found the hormonal response is sex- and cycle-dependent: women showed no response during the follicular phase of their cycle, meaning the effect is far less predictable and universal than a simple "testosterone booster" framing suggests.

Cancer Risk — What's Actually KnownNo study has found kisspeptin-10 itself causes cancer. The theoretical link people sometimes raise: it works by raising downstream sex hormones (testosterone, estrogen), and some cancers (like prostate and breast) are hormone-sensitive — meaning their growth can be fueled by exactly those hormones in someone who already has one of those cancers. That's a reason those specific cancers get treated with hormone-blocking drugs, not evidence that kisspeptin-10 itself is carcinogenic — but it's the relevant mechanism to know about, not a "no possible connection at all" situation.

Positive FindingsPrasse et al. 2010, American Journal of Respiratory and Critical Care Medicine — in an open-label trial, 20 patients with active sarcoidosis given inhaled VIP for 4 weeks showed significantly reduced inflammatory (TNF-alpha) production from lung immune cells and an increase in regulatory T cells, with good tolerability.

Negative Findings / LimitationsThis trial was small and open-label (not blinded or placebo-controlled), and tested one specific lung disease — it does not test the broader mold-illness or general anti-inflammatory protocols VIP is often used for.

Cancer Risk — What's Actually KnownNo trial of VIP as a therapy has found it causes cancer. Separate cancer-biology research has found VIP receptors are expressed on a number of tumor types, and VIP's role in that research is genuinely mixed — sometimes studied as something tumors exploit for their own growth signaling, sometimes explored as a way to target imaging or treatment at tumors that express its receptor. That's tumor-biology research, not evidence that using VIP as a treatment causes cancer.

YouTube VideosNo dedicated video coverage found in this library yet.

Positive FindingsAmirzargar et al. 2012 — in infertile men after varicocele surgery, HCG improved sperm morphology, with a 32% pregnancy rate vs. 0% in untreated men.

Negative Findings / LimitationsTwo separate double-blind trials — Young, Fuchs & Woltjen 1976, JAMA (202 patients) and Bosch et al. 1990 (40 women) — both found HCG produced no weight-loss benefit over placebo, meaning the well-known "HCG diet" effect comes from its accompanying very-low-calorie regimen, not the hormone itself.

Cancer Risk — What's Actually KnownWorth clarifying since this can sound alarming out of context: HCG isn't linked to causing cancer — if anything, it's used clinically as a tumor marker, meaning doctors measure a person's existing HCG levels to help detect or monitor certain cancers (like testicular cancer and choriocarcinoma), because those tumors themselves produce HCG. That's the tumor causing elevated HCG, not HCG causing the tumor. Using HCG as a medication (for fertility or TRT support) is a completely different context and hasn't been shown to raise cancer risk.

Positive FindingsAmirzargar et al. 2012 — in men after varicocele surgery, HMG improved sperm motility and morphology, with a 57% pregnancy rate. Turkcapar et al. 2013 — in women with PCOS undergoing IVF, HMG achieved comparable pregnancy rates to recombinant FSH, with a lower rate of ovarian hyperstimulation (0% vs. 11.9%).

Negative Findings / LimitationsBecause it's a standard, well-established fertility-clinic drug rather than a novel "biohacking" peptide, there isn't much to add here beyond its established, narrow clinical role — this is one compound where the marketing and the science largely agree.

Positive FindingsKhavinson et al. 2014 — in cultured rat kidney cells, the AED tripeptide increased cell proliferation and reduced aging-marker expression. Lin'kova et al. 2016 — in human skin fibroblast cultures, it suppressed markers of cell breakdown and senescence.

Negative Findings / LimitationsNeither study tested cartilage tissue directly, and there is no human trial of any kind — the evidence is isolated rat kidney cells and human skin cells in a dish.

YouTube VideosNo dedicated video coverage found in this library yet.

Positive FindingsKhavinson et al. 2000 — female mice given long-term Vilon injections showed increased activity and endurance, extended lifespan, and fewer spontaneous tumors, with no adverse effects on hormone cycling.

Negative Findings / LimitationsThis is a rodent lifespan study only. Khavinson, Kuznik & Ryzhak 2013, sometimes cited as "clinical" evidence, is actually a narrative review written by the same research group that invented the peptide, not an independent controlled trial.

YouTube VideosNo dedicated video coverage found in this library yet.

Positive FindingsKuzubova et al. 2015 — in a rat model of chronic obstructive lung disease, Bronchogen reversed goblet-cell overgrowth and epithelial damage and increased secretory immune protein (IgA) levels.

Negative Findings / LimitationsMonaselidze et al. 2011 — a separate test-tube biophysics experiment found Bronchogen stabilizes DNA structure, but this is a lab measurement, not a physiological one — and no human lung trial exists.

Cancer Risk — What's Actually KnownNo cancer signal has been reported for Bronchogen. Worth flagging only because of the DNA-binding finding above: any compound shown to directly interact with DNA structure naturally raises the question of whether it could also affect how DNA is copied or repaired (relevant to mutation and cancer risk), but that specific question hasn't been studied for Bronchogen — the existing finding is a physics measurement of DNA stability, not a genotoxicity or mutagenicity study.

YouTube VideosNo dedicated video coverage found in this library yet.

Positive FindingsChalisova et al. 2009 — in heart-tissue explants from young and old rats, Cardiogen stimulated cell growth more than any of 20 individual amino acids tested, in both age groups.

Negative Findings / LimitationsThis is a single ex vivo tissue-culture experiment measuring cell counts — no cardiac-function, survival, or human study of any kind exists.

Cancer Risk — What's Actually KnownThe same study also reported decreased p53 expression (a major tumor-suppressor gene involved in programmed cell death) alongside the increased cell growth — that combination is exactly the mechanistic pattern behind the general caution on this page: a signal that pushes cells to divide more while a brake on cell death is turned down doesn't have a way to tell a healthy heart cell apart from an abnormal one doing the same thing. No cancer outcome has actually been studied here — this is a single lab tissue-culture finding, not a documented cancer signal — but it's a more specific reason for caution than most entries on this page, not just a generic one.

YouTube VideosNo dedicated video coverage found in this library yet.

Positive FindingsZarubina & Shabanov 2011 — in rats with chronic brain ischemia, Cortagen accelerated behavioral/neurological recovery and reduced oxidative damage in brain tissue.

Negative Findings / LimitationsAnisimov, Khavinson & Anisimov 2004 — found Cortagen also measurably altered heart (not just brain) gene expression in mice, which undercuts the "brain-specific" targeting the marketing implies. No human trial exists.

YouTube VideosNo dedicated video coverage found in this library yet.

Positive FindingsControlled studies of trained cyclists have measured real, significant improvements in oxygen-carrying capacity and endurance performance from EPO use — this is precisely why it became sport's most notorious doping agent.

Negative Findings / LimitationsJelkmann & Lundby 2011, Blood and Reichel & Gmeiner 2010 — both review EPO's real, serious risks (raising blood thickness and clotting risk) and its status as a banned, actively-detected doping agent in endurance sports. Its legitimate medical use is strictly for diagnosed anemia under supervision, not performance enhancement.

Cancer Risk — What's Actually KnownUnlike most entries on this page, this isn't theoretical: clinical trials giving EPO-class drugs to cancer patients for chemotherapy-related anemia found worse tumor progression and higher mortality in several trials, which led the FDA to add a boxed warning specifically for use in cancer patients and to restrict that use. Some tumor types express EPO receptors, giving a plausible mechanism (the drug feeding the same growth signal in the tumor that it's meant to give red blood cells). This warning applies specifically to people who already have cancer being treated with EPO for anemia — it's a real, documented signal in that population, not evidence that EPO causes cancer in someone who doesn't have it, which hasn't been separately established.

YouTube VideosNo dedicated video coverage found in this library for CagriSema specifically — see the individual Semaglutide and Cagrilintide cards above for videos on each component.

YouTube VideosNo dedicated video coverage found in this library for the Retatrutide/Cagrilintide combination specifically — see the individual Retatrutide and Cagrilintide cards above for videos on each component.